Press Releases


Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier

Company Expands its Pterostilbene Based Portfolio into Brain Cancers

OCEANSIDE, Calif., July 16, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pterostilbene formulated for intranasal delivery.

Intranasal delivery is used with the intention to deliver high concentrations of substances into the brain across what is called the “blood-brain barrier.” This structure is a “security system” that keeps blood cells separate from the fluid surrounding the brain. This barrier does provide oxygen and nutrients to be transported by the blood cells but prevents harmful substances like bacteria or poisons from getting to the brain. While compounds such as pterostilbene [1,2], and alpha lipoic acid [3], can bypass the BBB, it is anticipated that higher concentrations can be delivered through the intranasal route.

“Our pharmacokinetic trial data showed a 55% increase in serum concentration of nanoparticle pterostilbene over a powdered and capsule form. We are therefore pleased to release a formulation of this product with double the potency and half-life over traditional powder formulation for intranasal use,” said Timothy Dixon, President, and CEO. “Late last year we filed a patent on the synergistic inhibition of glioma using pterostilbene. Our data suggest that when pterostilbene is combined with brain cancer therapeutics such as Temozolomide, Sertraline, or Gefitinib, their prognosis is improved. Furthermore, we observed that pterostilbene causes an increase of immunogenicity in chemotherapy-treated cancer cells, providing heightened immunity to cancer cells that escaped chemotherapy, theoretically enhancing patient prognosis,” added Mr. Dixon.

“The pterostilbene molecule has numerous potential applications in neurology and neuro-oncology. The generation of an intranasal formulation of pterostilbene opens the door for evaluating this molecule in a rapid manner in glioma and other brain cancer patients, where safe therapeutics with favorable safety profiles are urgently needed,” said Dr. Santosh Kesari, MD, Ph.D., and member of the Company’s Scientific Advisory Board.

“We are working on integrating NeuroStilbene into various protocols that are currently in development in order to enhance therapeutic options to patients with dreaded conditions such as brain tumors and neurodegenerative diseases,” stated Dr. James Veltmeyer, Chief Medical Officer of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is

[1] Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 2016 Sep 1; 76(17): 49704980.

[2] Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.Int J Mol Sci. 2018 Jan 18;19(1).

[3] Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.